B. Riley downgraded Augmedix to Neutral from Buy with a price target of $2.35, down from $3, after the company entered into a definitive agreement to be acquired by Commure for $2.35 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUGX:
- Augmedix to Join Forces with Commure
- Augmedix Discusses AI Tool Success and Expansion Plans
- Augmedix says Go ED has met HCA’s criteria for expansion
- Emergency Services Inc. Partners with Augmedix to Introduce Generative AI Solution That Relieves Clinician Burnout in Emergency Departments
- Augmedix, Emergency Services team to introduce GenAI solution